Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer

Ken Imaizumi1,2,3 | Toshihiro Suzuki2 | Motohiro Kojima4 | Manami Shimomura2 | Naoki Sakuyama1 | Yuichiro Tsukada1 | Takeshi Sasaki1 | Yuji Nishizawa1 | Akinobu Taketomi3 | Masaaki Ito1 | Tetsuya Nakatsura2

1Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
2Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan
3Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
4Division of Pathology, National Cancer Center Hospital East, Kashiwa, Japan

Abstract

Chemoradiotherapy (CRT) is the standard neoadjuvant therapy for locally advanced rectal cancer (RC). However, neoadjuvant chemotherapy (NAC) also shows favorable outcomes. Although the immunological environment of RC has been thoroughly discussed, the effect of NAC on it is less clear. Here, we investigated the immunological microenvironment, including T cell infiltration, activation, and topological distribution, of resected RC tissue after neoadjuvant therapies and evaluated the correlation between T cell subsets and patient prognosis. Rectal cancer patients (n = 188) were enrolled and categorized into 3 groups, namely CRT (n = 41), NAC (n = 46), and control (surgery alone; n = 101) groups. Characterization of residual carcinoma cells and T cell subsets in resected tissues was performed using multiplexed fluorescent immunohistochemistry. The densities of total and activated (Ki67high) T cells in tissues after NAC, but not CRT, were higher than in control. In both CRT and NAC groups, patients presenting with higher treatment effects showed aggressive infiltration of T cell subsets into carcinomas. Multivariate analyses of pathological and immunological features and prognosis revealed that carcinoma Ki67highCD4+ T cells after CRT and stromal Ki67highCD8+ T cells after NAC are important prognostic factors, respectively. Our results suggest that evaluation of T cell activation with Ki67 expression and its tumor localization can be used to determine the prognosis of advanced RC after neoadjuvant therapies.

Keywords
multiplexed fluorescent immunohistochemistry, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy, rectal cancer, tumor-infiltrating lymphocyte
The current standard treatment for locally advanced rectal cancer (RC) is preoperative chemoradiotherapy (CRT). Although CRT is known to improve local control of the tumor, it is also reported to cause postoperative complications and pelvic dysfunction.\(^1\)\(^4\) To maintain the function of pelvic nerves and muscles, neoadjuvant chemotherapy (NAC) was recently established.\(^5\)\(^6\) Tailored treatments, in which choosing or combining CRT and NAC is made on a case-by-case basis, will be significant in the future.\(^7\)

It has been reported that tumor-infiltrating lymphocytes (TILs) determine not only antitumor surveillance but also the treatment efficacy of neoadjuvant therapy.\(^8\)\(^9\) Tumor-infiltrating lymphocytes positively control tumor immunity and their marked infiltration was reported to be associated with better clinical outcomes in various cancers.\(^10\)\(^-\)\(^13\) High accumulation of intratumoral CD8\(^+\) T cells shows favorable prognosis in RC patients with or without preoperative CRT.\(^14\)\(^15\) However, no study has evaluated the immunological environment of RC after NAC. Evaluating changes in the immunological environment after neoadjuvant therapies could reveal immune cell components associated with treatment efficacy and patient prognosis. Currently, combination studies with immunological checkpoint inhibitors, chemotherapy, radiotherapy, and CRT are underway for various tumors to enhance the antitumor immune response.\(^7\)\(^16\)\(^17\) Although some clinical trials revealed that immunological checkpoint inhibitors, such as mAbs against programmed cell death-1, are effective against various cancers,\(^16\)\(^18\) most advanced colorectal cancers, excluding high microsatellite instability colorectal cancer, are insensitive to immunological checkpoint inhibitors.\(^19\) Thus, assessing the immunological environment and its effect on antitumor immune response after neoadjuvant therapies could provide a proof of concept for the benefits of immune checkpoint inhibitors in combination with CRT and NAC for advanced RC treatment.

Recently, multiplex fluorescence immunohistochemistry (mFIHC) has emerged as an effective tool for comprehensive analysis of immune cell type in the tumor microenvironment.\(^20\)\(^-\)\(^22\) Previously, studies evaluated stromal or intratumoral lymphocytes in addition to analyzing TIL subsets and have reported that TIL localization in the epithelial compartment of tumors is important because nonspecific infiltration of lymphocytes into the tumor stroma is often observed after treatment.\(^23\)\(^24\) The nuclear protein Ki67 is commonly used to assess cell proliferation and measure the proliferative capacity of tumor cells and T cells. Ki67 expression is observed during all active phases of cell division but not during DNA repair or the cell quiescent phase.\(^25\) For some chronic diseases, such as HIV infection, cancer, and autoimmune diseases, the Ki67 expression pattern in T cells is used to evaluate antigen-specific T cell expansion.\(^26\)\(^27\)

In this study, using mFIHC analysis by staining with opal fluorescence molecules and multispectra imaging, we analyzed the tumor microenvironment and immunological features of RC, including T cell activation by Ki67 expression, and elucidated the histological alterations mediated by NAC and CRT compared with surgery alone. Moreover, we evaluated the correlation between TIL subsets and recurrence-free survival (RFS) to find novel prognostic markers after neoadjuvant therapies.

## 2 | MATERIALS AND METHODS

### 2.1 | Patient cohort

Ninety-nine locally advanced RC patients (T3 or T4, N0 or T any, N1-2) who had received preoperative therapy between January 2001 and June 2014 at the National Cancer Center Hospital East (NCCH, Chiba, Japan) were recruited. Of these, 48 and 51 cases received preoperative CRT and NAC, respectively. The CRT group received preoperative fluoropyrimidine-based chemotherapy (infused 5-fluorouracil or oral capecitabine) and fractionated radiation (total 45 Gy in 25 fractions or total 50.4 Gy in 28 fractions). Surgical resection was performed 4-12 weeks after CRT. The NAC group received 3-8 courses of preoperative FOLFOX, followed by surgery 4-8 weeks after NAC. Seven patients in the CRT group and 5 patients in the NAC group achieved pathological complete response (pCR). These 12 cases with pCR were excluded because of no detectable cancer tissue in the resected specimens. As control subjects, 101 patients who underwent surgery alone were recruited. Finally, 188 patients with locally advanced RC were enrolled and categorized into 3 groups according to pretreatment: CRT group (n = 41), NAC group (n = 46), and control group (n = 101). The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of NCCH (protocol no. 2016-157).

### 2.2 | Histopathology

Preoperative clinical staging and pathological staging were carried out according to the UICC classification (7th edition). The local treatment effect was evaluated by tumor regression grade (TRG) according to the method described by the American Joint Committee on Cancer and the College of American Pathologists.\(^28\)\(^29\) Other variables obtained from the pathology report were pathological stage (pStage and ypStage), lymphatic invasion (LYI), vascular invasion (VI), and perineural invasion (PNI).

### 2.3 | Construction of 4-point tissue microarrays

Formalin-fixed, paraffin-embedded tumor blocks and corresponding slides stained with H&E from the 188 cases were collected from the institutional pathology archive. For tissue microarray (TMA), a gastrointestinal pathologist selected 2 target areas from the center of the tumor and the invasive margin, after which a total of 4 tumor cores per case were picked up using a punch tip (φ 2 mm; Azumaya) (Figure S1A,B).\(^30\)\(^31\) One TMA block contained 48 tissue cores; in total, 16 TMA sets consisting of 768 core specimens were prepared for this study.
2.4 | Immunohistochemistry for mismatch repair status

To identify mismatch repair (MMR) status, we performed conventional immunohistochemistry (IHC) using MLH1 (1:500; BD Pharmingen), MSH2 (1:50; Calbiochem), MSH6 (1:1000; BD Pharmingen), and PMS2 (1:50; Dako, Santa Clara, CA) Abs. Immunohistochemistry was carried out on 4-µm thick sections obtained from the TMA block (Figure S1C). Tumor cell nuclei that did not display any brown staining for the abovementioned markers were considered MMR deficient (dMMR).

2.5 | Multiplex fluorescence IHC and image analysis

Tissue sections (4-µm thick) obtained from TMA blocks were subjected to mFIHC staining using the PerkinElmer Opal Kit (PerkinElmer). The Abs, dilutions, and activation conditions used are listed in Table S1. Images were captured using an automated multisector imaging system (Vectra version 3.0; PerkinElmer). An image analysis program (Inform; PerkinElmer) was used to segment tumor tissues into carcinoma and stromal areas and to detect immune cells with specific phenotypes, after which the distribution of immune cells was analyzed (Figure S2). Training sessions for tissue segmentation and phenotype recognition were carried out repeatedly until the algorithm reached the level of confidence recommended by the program supplier (at least 90% accuracy) before performing the final evaluation. After phenotyping typical CD4+ and CD8+ cells using Inform software, gated CD3+ populations by mean fluorescence intensity of CD3, CD3+CD4+, and CD3+CD8+ cells were determined as CD4+ T cells and CD8+ T cells, respectively. A similar gating strategy was used for the analysis of Ki67+ population in cytokeratin positive (CK+) cells, CD4+ T cells, and CD8+ T cells using an analytical program (Spotfire version 7.8; TIBCO Software; Figure S3). The area of each tissue category, carcinoma and stroma, was evaluated to assess the density of lymphocytes, represented by (number of lymphocytes)/ (pixel area) in each tumor core; an average value of 4 tumor cores was determined. T cells in the carcinoma and stromal areas were defined as carcinoma T cells and stromal T cells, respectively. The ratio of carcinoma to stromal T cells (carcinoma / stromal ratio) was calculated using the ratio of the density of carcinoma T cells to that of stromal T cells.

2.6 | Statistical analysis

Densities of the lymphocyte subsets were represented using box plots with median values and interquartile ranges. The boxplot whiskers indicate the 10th and 90th percentile values. Bar charts show mean values of proportion and ratios of each population.

| TABLE 1 | Characteristics of patients with rectal cancer |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic   | CRT (n = 41)    | NAC (n = 46)    | Control (surgery alone) (n = 101) | P value CRT vs NAC | P value CRT vs Cont. | P value NAC vs Cont. |
| Age (years), median (range) | 57 (27-77) | 57 (27-72) | 61 (33-80) | .739 | .340 | .053 |
| Sex, n (%)       |                |                |                |                |                |                |
| Male             | 30 (73.2)      | 33 (71.7)      | 66 (65.3)      | 1.000          | 1.000          | 1.000          |
| Female           | 11 (26.8)      | 13 (28.3)      | 35 (34.7)      |                |                |                |
| Distance from anal verge (cm), median (range) | 3.0 (0-6.0) | 3.5 (0-6.0) | 4.0 (0-6.0) | .266 | .116 | .996 |
| Clinical TNM stage, n (%) |                |                |                |                |                |                |
| II               | 18 (43.9)      | 18 (39.1)      | 54 (53.5)      | 1.000          | 1.000          | 0.450          |
| III              | 23 (56.1)      | 28 (60.9)      | 47 (46.5)      |                |                |                |
| Pathological TNM stage, n (%) |                |                |                |                |                |                |
| I                | 10 (24.4)      | 13 (28.3)      | 22 (21.8)      | 1.000          | 1.000          | 1.000          |
| II               | 14 (34.1)      | 12 (26.1)      | 35 (34.7)      |                |                |                |
| III              | 17 (41.5)      | 21 (45.6)      | 44 (43.5)      |                |                |                |
| Lymphatic invasion, n (%) | 10 (24.4) | 22 (47.8) | 53 (52.5) | .124 | .012 | 1.000 |
| Vascular invasion, n (%) | 24 (58.5) | 21 (45.7) | 82 (81.2) | .973 | .028 | <.001 |
| Perineural invasion, n (%) | 14 (34.1) | 12 (26.1) | 43 (42.6) | 1.000 | 1.000 | .250 |
| Tumor regression grade, n (%) |                |                |                |                |                |                |
| 1                | 17 (41.5)      | 13 (28.3)      | —              | <.001          |                |                |
| 2                | 24 (58.5)      | 20 (43.5)      | —              |                |                |                |
| 3                | 0 (0)          | 13 (28.3)      | —              |                |                |                |
| dMMR, n (%)      | 3 (7.3)        | 2 (4.3)        | 6 (5.9)        | 1.000          | 1.000          | 1.000          |

Abbreviations: —, not applicable; Cont., Control; CRT, chemoradiotherapy; dMMR, deficient mismatch repair; NAC, neoadjuvant chemotherapy.
3 | RESULTS

3.1 | Patient characteristics and RFS after neoadjuvant therapies

Patient characteristics and clinicopathological features are listed in Table 1. There were no significant differences in age, sex, distance from anal verge, clinical TNM stage, pathological TNM stage, or PNI between the 3 groups. Lymphatic invasion was observed less frequently in the CRT group than in the control group. Vascular invasion was also found less frequently in the CRT and NAC groups than in the control group. Tumor regression grade in the CRT group was better than in the NAC group. Eleven patients (5.9%) were dMMR, of which 3 patients (7.3%) were in the CRT group, 2 (4.3%) in the NAC group, and 6 (5.9%) in the control group. There were no significant differences in RFS based on neoadjuvant therapies (3-year RFS, CRT 60.6% vs NAC 63.0%; P = .976).

3.2 | Changes in histology and growth activity of residual carcinoma areas after neoadjuvant therapies

Using mFIHC analysis of tumor sections with nuclei, CK, and Ki67 staining, we compared the treatment effects of CRT and NAC based on residual carcinoma areas and their growth activity (Figure 1A). Calculation of the total carcinoma area by Inform software was highly correlated with TRG (Figure 1B). Interestingly, within the same TRG, the individual regions of residual carcinomas in the CRT group (Figure 1A, center panel) tended to be smaller than those in the NAC group (Figure 1A, right panel), although the total residual carcinoma area was comparable between them (Figure 1B). Patients who received CRT had smaller carcinoma masses (<0.01 mm^2) than those who received NAC and had the same TRG (Figure 1C). To examine the inhibition of residual carcinoma growth by each neoadjuvant therapy, we evaluated Ki67 expression in CK^+ cells and found that the growth activity of CK^+ cells was significantly inhibited by CRT, but not by NAC (Figure 1D). Moreover, the proportion of Ki67^hi in CK^+ cells was not altered by the local treatment effects of either CRT or NAC (Figure 1E).

3.3 | Analysis of T cells and their localization in tumor tissue after neoadjuvant therapies

Representative features of CD3/CD4 and CD3/CD8 double staining for surgery alone, CRT, and NAC specimens are shown in Figure 2A, B. Compared with the control group, the densities of carcinoma CD4^+ T cells, carcinoma CD8^+ T cells, and stromal CD8^+ T cells were significantly increased after NAC. In the CRT group, the densities of carcinoma CD4^+ T cells and CD8^+ T cells were preserved compared with those in the control group, whereas the densities of stromal CD4^+ T cells and CD8^+ T cells were significantly reduced (Figure 2C, D). After CRT, the carcinoma / stromal ratio of both CD4^+ and CD8^+ T cells was significantly higher than in the control group, whereas after NAC, only CD8^+ T cells tended to infiltrate the carcinoma area (Figure 2E).

3.4 | Analysis of the Ki67^hi subpopulation of T cells after neoadjuvant therapies

Next, we assessed the population of Ki67^hi T cells in each tissue area to assess T cell activity. Representative images of Ki67 staining in CD4^+ and CD8^+ T cells are shown in Figure 3A, B, respectively. Similar to total T cells, the densities of carcinoma and stromal Ki67^hiCD4^+ T cells in the NAC group were significantly increased compared with the control group. The density of carcinoma Ki67^hiCD8^+ T cells after NAC also tended to increase.
Moreover, the proportion of Ki67$^{\text{high}}$CD4$^+$ T cells after NAC increased, whereas that of Ki67$^{\text{high}}$CD8$^+$ T cells did not change compared with that of the control group. Regarding the CRT group, the densities of stromal Ki67$^{\text{high}}$CD4$^+$ T cells as well as carcinoma and stromal Ki67$^{\text{high}}$CD8$^+$ T cells were significantly decreased compared with that of the control group; however, the proportions of
FIGURE 2  Evaluation of tumor-infiltrating T cells after neoadjuvant therapies for rectal cancer. A, Representative multiplex fluorescence images of tumor-infiltrating T cells after neoadjuvant therapies. Nuclei, CD3, CD4, CD8, and cytokeratin in cells are shown in gray, blue, green, red, and orange, respectively. B, Enlarged fluorescence images show CD3^+CD4^+ cells as CD4^+ T cells (upper panels) and CD3^+CD8^+ cells as CD8^+ T cells (lower panels). C, D, Carcinoma (left graph) and stromal (right graph) CD4^+ T cell (C) and CD8^+ T cell (D) density. P values were analyzed by the Steel test. E, Ratio of carcinoma to stromal CD4^+ T cells (left graph) and CD8^+ T cells (right graph). P values were analyzed by Dunnett’s test. Cont., control; CRT, chemoradiotherapy; NAC, neoadjuvant chemotherapy.
Ki67$^\text{high}$ T cells, except for carcinoma Ki67$^\text{high}$CD8$^+$ T cells, were comparable (Figure 3C–F). Both CRT and NAC groups showed no significant differences in the carcinoma / stromal ratio of Ki67$^\text{high}$ T-cell subsets; the ratio of Ki67$^\text{high}$CD4$^+$ T cells was higher in the CRT group, whereas the ratio of Ki67$^\text{high}$CD8$^+$ T cells was higher after NAC (Figure 3G).
3.5 | Correlation between T cell subsets and local treatment effect

Subsequently, to evaluate the role of T cell subsets on local treatment effects, we evaluated the correlation between T cell subset localization and TRG. The density of each T cell subset for each TRG patient is shown in Figure S4. After CRT, the densities of stromal T cells in all TRG patients were decreased, whereas the densities of carcinoma T cells in TRG1 patients were maintained. After NAC, the densities of carcinoma T cells tended to increase in all TRG patients; stromal T cells showed a similar increasing trend, with the exception of TRG1 patients. The carcinoma / stromal ratios showed more prominent results and were significantly higher in TRG1 patients after both neoadjuvant therapies than in the control group (Figure 4A, B). In particular, there was a marked increase in carcinoma / stromal ratios of Ki67high subsets compared with that of total subsets (Figure 4C, D). Although CD4+ and CD8+ T cell density in the carcinoma or stromal areas showed different behaviors between CRT and NAC, T cells infiltrated the carcinoma area more readily after both neoadjuvant therapies, especially in patients who experienced significant tumor regression.

Because the Foxp3 transcriptional factor is well known as a marker of regulatory T cells (Tregs)—a subset of CD4+ T cells that have a strong immunosuppressive function34-37—we examined the effects of CRT and NAC on Treg subsets by Foxp3 staining (Figure S5A). The proportion of Foxp3high Tregs in the stromal CD4+ T cell subset was decreased after neoadjuvant therapies (Figure S5B, C), which was associated with the treatment effects (TRG) of both neoadjuvant therapies (Figure S5D). In contrast, the proportion of the Treg subset in carcinomas did not change among the 3 groups. We also analyzed the role of macrophages as immunosuppressive cells (Figure S6A, B). CD68+ macrophages increased significantly after NAC and tended to increase after CRT (Figure S6C). Analysis of the CD68+ population based on the M1 (CD68+CD204−) and M2 (CD68+CD204+) macrophage phenotypes revealed that M1 levels increased significantly after both CRT and NAC (Figure S6D).

3.6 | Contributions of Ki67high T cells to RFS after neoadjuvant therapies

To assess the effects of T cell subsets on prognosis, we classified patients in the CRT and the NAC groups as high or low cases using the median of T cell densities and carcinoma / stromal ratios. Univariate Cox proportional hazards analysis indicated that the densities of both Ki67highCD4+ and CD8+ T cells were associated with better prognosis; the high densities of carcinoma Ki67highCD4+ T cells after CRT and stromal Ki67highCD8+ T cells after NAC could significantly inhibit recurrence. The densities of CD4+ and CD8+ T cells in the CRT group and CD8+ T cells in the NAC group tended to be associated with better prognoses, although the differences were not statistically significant. In contrast, there were no differences in the carcinoma / stromal ratios between the high and low cases (Table 2).
Finally, we applied the univariate analysis and the following multivariate Cox proportional hazards analysis to assessing the importance of various covariates in pathological features and T cell subsets for RFS. We found that LYI as well as the densities of carcinoma Ki67\textsuperscript{high}CD4\textsuperscript{+} T cells after CRT and stromal Ki67\textsuperscript{high}CD8\textsuperscript{+} T cells after NAC were significantly independent predictive factors (Table 3). Kaplan-Meier analysis of RFS using the density of these T cell subsets in both the CRT and NAC groups is shown in Figure 5.

| T-cell subset | CRT (n = 41) | | | NAC (n = 46) | | |
|--------------|-------------|-----------|-------------|----------------|-----------|
|               | HR         | 95% CI    | P value    | HR            | 95% CI    | P value |
| Carcinoma CD4\textsuperscript{+} T cells (high/low) | 0.497 | 0.192-1.285 | .149 | 1.005 | 0.408-2.476 | .991 |
| Stromal CD4\textsuperscript{+} T cells (high/low) | 0.914 | 0.362-2.306 | .849 | 0.945 | 0.383-2.327 | .901 |
| Carcinoma CD8\textsuperscript{+} T cells (high/low) | 0.389 | 0.146-1.038 | .059 | 0.502 | 0.198-1.277 | .148 |
| Stromal CD8 T cells (high/low) | 0.510 | 0.197-1.316 | .164 | 0.484 | 0.190-1.231 | .128 |
| Carcinoma / stromal ratio of CD4\textsuperscript{+} T cells (high/low) | 0.885 | 0.351-2.232 | .796 | 1.102 | 0.448-2.716 | .832 |
| Carcinoma / stromal ratio of CD8\textsuperscript{+} T cells (high/low) | 0.828 | 0.327-2.100 | .691 | 1.044 | 0.424-2.570 | .926 |
| Carcinoma Ki67\textsuperscript{high}CD4\textsuperscript{+} T cells (high/low) | 0.366 | 0.137-0.979 | .045 | 0.747 | 0.300-1.860 | .531 |
| Stromal Ki67\textsuperscript{high}CD4\textsuperscript{+} T cells (high/low) | 0.471 | 0.182-1.219 | .121 | 0.739 | 0.297-1.839 | .516 |
| Carcinoma Ki67\textsuperscript{high}CD8\textsuperscript{+} T cells (high/low) | 0.513 | 0.199-1.325 | .168 | 0.492 | 0.194-1.253 | .137 |
| Stromal Ki67\textsuperscript{high}CD8 T cells (high/low) | 0.517 | 0.200-1.335 | .173 | 0.377 | 0.143-0.994 | .049 |
| Carcinoma / stromal ratio of Ki67\textsuperscript{high}CD4\textsuperscript{+} T cells (high/low) | 1.403 | 0.553-3.562 | .476 | 1.172 | 0.476-2.888 | .730 |
| Carcinoma / stromal ratio of Ki67\textsuperscript{high}CD8\textsuperscript{+} T cells (high/low) | 1.319 | 0.520-3.346 | .560 | 1.154 | 0.469-2.842 | .755 |

Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; NAC, neoadjuvant chemotherapy.

### 4 | DISCUSSION

In this study, we first assessed the effect of neoadjuvant therapies, CRT and NAC, on the tumor microenvironments of advanced RC. While CRT and NAC had different effects on the density of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells in tumor tissues, the aggressive migration of TILs into tumor tissues, and causing fibrosis.40 Additionally, cumulative DNA damages not only the carcinoma but also the normal tissue around it, including the tumor stroma, by inducing apoptosis, disrupting whole tumor tissues, and causing fibrosis.40 Additionally, cumulative DNA damage in residual carcinoma cells, resulting from fractionated irradiation, causes longer growth suppression of carcinoma cells.

After evaluating lymphocyte infiltration, we found an increased density of TILs after NAC of RC. Similarly, Tsuchikawa et al\textsuperscript{41} reported that the CD4\textsuperscript{+} and CD8\textsuperscript{+} cell count is increased after neoadjuvant chemotherapy of esophageal squamous cell carcinoma. Chemotherapy induces the accumulation of CD4\textsuperscript{+} cells in tumors via inflammatory responses and is accompanied by an upregulation of chemokines.42 However, this study and our previous reports found that the T cell density in tumor tissues decreased after CRT.\textsuperscript{43} Conversely, Shinto et al\textsuperscript{44} reported that the number of stromal CD8\textsuperscript{+} cells in RC increased after neoadjuvant CRT. These discrepancies in immunological observations after CRT might be due to the radiation dose and interval time between the last irradiation to resection; in
| Factor                              | CRT (n = 41) | Multivariate analysis | NAC (n = 46) | Multivariate analysis |
|------------------------------------|--------------|-----------------------|--------------|-----------------------|
|                                    | n            | Univariate analysis   | n            | Univariate analysis   |
|                                    |              | HR (95% CI) P value   |              | HR (95% CI) P value   |
|                                    |              |                       |              |                       |
| Pathological TNM stage             |              |                       |              |                       |
| I                                  | 10           | 0.307 (0.071-1.339) .116 | 13           | 0.109 (0.015-0.817) .031 |
| II/III                             | 31           | Ref                   | 33           | Ref                   |
|                                    |              | —                     |              |                       |
| Lymphatic invasion                 |              |                       |              |                       |
| Present                            | 10           | 3.076 (1.176-8.046) .022 | 22           | 2.251 (0.886-5.720) .088 |
| Absent                             | 31           | Ref                   | 24           | Ref                   |
|                                    |              |                       |              |                       |
| Vascular invasion                  |              |                       |              |                       |
| Present                            | 24           | 0.829 (0.327-2.100) .692 | 21           | 4.532 (1.628-12.62) .004 |
| Absent                             | 17           | Ref                   | 25           | Ref                   |
|                                    |              |                       |              |                       |
| Perineural invasion                |              |                       |              |                       |
| Present                            | 14           | 2.548 (1.009-6.435) .048 | 12           | 3.646 (1.469-9.045) .005 |
| Absent                             | 27           | Ref                   | 34           | Ref                   |
|                                    |              |                       |              |                       |
| Tumor regression grade             |              |                       |              |                       |
| 1                                  | 17           | 0.597 (0.224-1.595) .304 | 13           | 0.809 (0.291-2.248) .685 |
| 2/3                                | 24           | Ref                   | 33           | Ref                   |
|                                    |              |                       |              |                       |
| Carcinoma Ki67<sup>+</sup>CD4<sup>+</sup> T cells | | | | |
| High                               | 21           | 0.366 (0.137-0.979) .045 | 23           | 0.747 (0.300-1.860) .531 |
| Low                                | 20           | Ref                   | 23           | Ref                   |
|                                    |              |                       |              |                       |
| Stromal Ki67<sup>+</sup>CD8<sup>+</sup> T cells | | | | |
| High                               | 21           | 0.517 (0.200-1.335) .173 | 23           | 0.377 (0.143-0.994) .049 |
| Low                                | 20           | Ref                   | 23           | Ref                   |

Abbreviations: —, not applicable; CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; NAC, neoadjuvant chemotherapy; Ref, reference.
In the present study, surgical resection was carried out 4-12 weeks after neoadjuvant CRT at 45 to 50.4 Gy, whereas, for Shinto et al., resection was carried out 4 weeks after irradiation with 20 Gy. Long-term fractionated irradiation on local tumors results in transient lymphopenia in tumor tissues, accompanied by tumor regression. Moreover, our results of increased T cells in cancer tissues after NAC could support a combination therapy with immunological checkpoint blockade for RC. Our findings highlight the importance of combination therapies with radiotherapy and cancer immunotherapy; short-term fractionated irradiation and longer interval times could be optimal for the preservation of immunological surveillance against cancer.

Despite the different effects of the neoadjuvant therapies on T cell density, both therapies induced the aggressive infiltration of TILs into carcinoma masses, accompanied by tumor regression. However, no significant correlation was observed between the carcinoma / stromal ratio of T cells and patient RFS. This finding indicates that there are different mechanisms between the antitumor immune response against the local tumor and the immune surveillance associated with suppression of systemic recurrence. Similar to a previous report regarding the effect of neoadjuvant therapies on antitumor immunity in other cancer types, our finding suggests that the antitumor immune response can be enhanced during neoadjuvant therapies of advanced RC via antigen spreading and the initiation of danger signals. Moreover, as baseline tumor size could be an independent prediction marker for the efficacy of immune checkpoint inhibitors, the combination of immune checkpoint inhibitors and neoadjuvant therapies for partial tumor reduction could be effective for RC treatment.

We further found that the correlation between important TIL subsets and their localization with prognosis differed between the CRT and NAC groups. For CRT, both Ki67-high CD4+ and Ki67-high CD8+ T cell density contributed to suppress systemic recurrence; in particular, an increased density of Ki67-high CD4+ T cells in the carcinoma area significantly prolonged RFS. Meanwhile, stromal Ki67-high CD8+ T cells after NAC mostly contributed to prolong RFS. Although the CD4+ population significantly increased after NAC, this population was not associated with improved RFS. These results suggest that different neoadjuvant therapies initiated immune surveillance against the tumors by different mechanisms; the helper function of CD4+ T cells is important after CRT, but not after NAC. The enhancement of cytotoxic T lymphocyte (CTL) activity by CRT (abscopal effect) was reported to require the function of helper CD4+ T cells through the activation of tumor-infiltrating antigen-presenting cells (APCs), such as tumor-associated macrophages and dendritic cells. However, the activation of APCs after NAC would be induced nonspecifically without the help of CD4+ T cells because a robust infiltration of T cells accompanied by the inflammatory response was observed in the local tumor site. Therefore, enhancement of CTL activity could occur independently of CD4+ T cell activation during NAC.

Regarding the role of the immunosuppressive population, we found that the proportion of carcinoma Tregs did not change among the 3 groups, whereas stromal Tregs were significantly decreased and accompanied by tumor regression. The Treg density after NAC increased, but this was associated with the increase in total CD4+ T cells. These findings suggest that the selective depletion of stromal Tregs by neoadjuvant therapies leads to the infiltration of activated CTL, followed by local tumor elimination. After analyzing tumor-infiltrating macrophages, we found that both neoadjuvant therapies increased polarization towards M1 macrophages, which have been reported to robustly express MHC class II. Thus, we theorized that both CRT and NAC can polarize tumor-infiltrating macrophages, resulting in improvement of the tumor immune environment, which is similar to the depletion of stromal Tregs. Although neoadjuvant therapies could improve the local tumor immune environment, they did not contribute to the prolongation of RFS.

![Figure 5](image-url)  
**Figure 5** Kaplan-Meier curves of recurrence-free survival (RFS) after neoadjuvant therapies for rectal cancer according to the densities of Ki67-high T-cell subsets. (A) According to the densities of carcinoma Ki67-high CD4+ T cells (A) or Ki67-high CD8+ T cells (B), patients were classified into high or low groups based on the median value. RFS of patients who received chemoradiotherapy (CRT) or neoadjuvant chemotherapy (NAC) are shown as bold lines and dotted lines, respectively. The color range indicates the accumulation of lymphocytes, with high accumulation shown in red and low accumulation shown in black. P values were analyzed by a log-rank test.
(Table S2). We found that lower densities of Ki67$^{\text{high}}$CD4$^+$ and CD8$^+$ T cells tended to correlate with a lower infiltration of Tregs (data not shown), resulting in a shorter RFS. Further experiments are warranted to uncover the role of CD4$^+$ T cells in the antitumor immune response during neoadjuvant therapies, especially NAC.

In summary, we found that the evaluation of activated T cells expressing Ki67 and their localization in tumors is a reliable immunological marker for predicting the prognosis of locally advanced RC patients who received neoadjuvant therapy. Our results were also confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7). Previously, accumulation confirmed and practically validated by H&E staining and immunohistochemistry double staining (Figure S7.)

**ACKNOWLEDGMENTS**

We thank Eiichi Sato (Department of Pathology, Tokyo Medical University) for excellent technical support, Shogo Nomura (Department of Biostatistics, National Cancer Center Hospital East) for advice on statistical analysis, Yuka Nakamura (Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center) for technical assistance, and Mamoru Nomura (PerkinElmer) for advice on staining and image analysis. This work was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8).

**DISCLOSURE**

The authors report no conflict of interest.

**ORCID**

Ken Imaizumi [https://orcid.org/0000-0002-7751-6270](https://orcid.org/0000-0002-7751-6270)
Toshihiro Suzuki [https://orcid.org/0000-0002-7095-6556](https://orcid.org/0000-0002-7095-6556)
Mototaka Kojima [https://orcid.org/0000-0002-6150-6545](https://orcid.org/0000-0002-6150-6545)
Naoki Sakuyama [https://orcid.org/0000-0003-2711-1168](https://orcid.org/0000-0003-2711-1168)
Tetsuya Nakatsura [https://orcid.org/0000-0003-3918-2385](https://orcid.org/0000-0003-3918-2385)

**REFERENCES**

1. Bullard KM, Trudel JL, Baxter NN, et al. Primary perineal wound closure after preoperative radiotherapy and abdominoperineal resection has a high incidence of wound failure. *Dis Colon Rectum*. 2005;48:438-443.

2. Imaizumi K, Nishizawa Y, Ikeda K, et al. Extended pelvic resection for rectal and anal canal tumors is a significant risk factor for perineal wound infection: a retrospective cohort study. *Surg Today*. 2018;48:978-985.

3. Ito M, Saito N, Sugito M, et al. Analysis of clinical factors associated with anaplastic lymphoma kinase (ALK) expression and outcome in stage IIA and IIB non-small-cell lung cancer patients treated with neoadjuvant chemotherapy. *Ann Surg Oncol*. 2016;23:1423-1429.

4. Imaizumi K, Nishizawa Y, Ikeda K, et al. Extended pelvic resection for rectal and anal canal tumors is a significant risk factor for perineal wound infection: a retrospective cohort study. *Surg Today*. 2018;48:978-985.

5. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial. *J Clin Oncol*. 2014;32:513-518.

6. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. *J Clin Oncol*. 2016;34;3300-3307.

7. Rouanet P, Ruiller E, Lelong B, et al. Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy. *Dis Colon Rectum*. 2017;60:653-663.

8. McDonnell AM, Nowak AK, Lake RA. Contribution of the immune system to the chemotherapeutic response. *Semin Immunopathol*. 2011;33:333-367.

9. Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. *Immunity*. 2013;39:74-88.

10. Cho Y, Miyamoto M, Kato K, et al. CD4$^+$ and CD8$^+$ T cells cooperate to improve prognosis of patients with Esophageal squamous cell carcinoma. *Cancer Res*. 2003;63(1555-1559):11.

11. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med*. 2003;348:203-213.

12. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8$^+$ T cells and CD4$^+$ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. *Br J Cancer*. 2006;94:275-280.

13. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. *J Clin Oncol*. 2013;31:860-867.

14. Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. *Clin Cancer Res*. 2014;20:1891-1899.

15. Shintou E, Hase K, Hashiguchi Y, et al. CD8$^+$ and FOXP3$^+$ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. *Ann Surg Oncol*. 2014;21:434-421.

16. Yi JS, Ready N, Healy P, et al. Immune activation in early stage non-small cell lung cancer patients receiving neoadjuvant chemotherapy plus ipilimumab. *Clin Cancer Res*. 2017;23:7474-7482.

17. Rutkowski P, Kozak K. News from the melanoma sessions of the European Cancer Congress 2017. *BMC Med*. 2017;15:57.

18. Forde PM, Smith KN, Chaft JE, et al. Stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. *Ann Oncol*. 2016;27:vi552-vi587.

19. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015;372:2509-2520.
IMAIZUMI et al.

20. Cross M. ERG oncoprotein overexpression in prostate cancer. Multiplex IHC adds to diagnostic prowess and efficiency of labora-

21. Stack EC, Wang C, Roman KA, et al. Multiplexed immunohisto-

22. Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of forma-

23. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of col-

24. Igari F, Horimoto Y, Takahashi Y, et al. Diagnostic significance of intratumoral CD8+ tumor infiltrating lymphocytes in medullary car-

25. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces patient survival than microsatellite instability. Immunity. 2016;44:69-711.

26. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human im-

27. Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of forma-

28. Edge SB, Compton CC. The American Joint Committee on Cancer:

29. Mace AG, Pai RK, Stocchi L, et al. American joint committee on can-

30. Shinto E, Tsuda H, Ueno H, et al. Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal can-

31. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+

32. Takahashi D, Kojima M, Suzuki T, et al. Profiling the tumour immune

33. Kanda Y. Investigation of the freely available easy-to-use soft-

34. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.

35. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373-5380.

36. Mougiakakos D, Johannsson CC, Trocmé E, et al. Intratumoral forhead box P3-positive regulatory T cells predict poor sur-

37. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+

38. Peeters KC, Marjinen CAM, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carci-

39. Sakuyama N, Kojima M, Kawano S, et al. Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergo-

40. Kelley ST, Coppola D, Yeatman T, et al. Tumor response to neo-

41. Tsuchikawa T, Yamamura Y, Shichinohe T, et al. The immunologi-

42. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant che-

43. Joseph RW, Elsaissi-Schaap J, Kefferd R, et al. Baseline tumor size is an independent prognostic factor for overall survival in pa-

44. Gulley JL, Madan RA, Pachynski R, et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treat-

45. Kubo M, Satoh T, Ishiyama H, et al. Enhanced activated T cell sub-

46. Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013;4:e688-e696.

47. Wijesundera KK, Izawa T, Tennakoon AH, et al. M1- and M2-

48. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alter-

49. Hao J, Wu Z, Yang Y, et al. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci. 2020;111:23-35. https://doi.org/10.1111/cas.14223

50. Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgi-

SUPPORTING INFORMATION

Additional supporting information may be found in the Supporting Information section.